Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2015-12-07 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2015-12-07 English
FORM 4 -
Director's Dealing
2015-12-07 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an announcement of a change in compensation for an officer (Jeffrey Young), specifically an increase in salary and bonus target, and a grant of restricted stock units. This fits the category of management or board changes or related compensatory arrangements. The document also references a press release about company achievements but does not contain financial statements or detailed financial data. The primary focus is on management compensation changes, which aligns with the Board/Management Information category (MANG). The document length is 3406 characters, which is short and typical for an 8-K announcement rather than a full report. Therefore, the best classification is MANG with high confidence.
2015-12-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2015, reporting the company's financial results for the quarter ended September 30, 2015. It specifically mentions that the full text of the press release announcing these results is furnished as an exhibit (Exhibit 99.1) and that the information is furnished, not filed. The document is short (3124 characters) and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER).
2015-11-05 English
10-Q
Interim / Quarterly Report Q3 2015
2015-11-05 English
SC 13D
Major Shareholding Notification
2015-10-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.